Dariush Etemadmoghadam
Overview
Explore the profile of Dariush Etemadmoghadam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
6010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emery J, Jenkins M, Saya S, Chondros P, Oberoi J, Milton S, et al.
Br J Gen Pract
. 2023 Apr;
73(733):e556-e565.
PMID: 37012077
Background: A risk-stratified approach to colorectal cancer (CRC) screening could result in a more acceptable balance of benefits and harms, and be more cost-effective. Aim: To determine the effect of...
2.
Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36720497
Background: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options...
3.
Moujaber T, Etemadmoghadam D, Kennedy C, Chiew Y, Balleine R, Saunders C, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-14.
PMID: 35135122
Purpose: Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and is characterized by activating mutations in the Ras sarcoma-mitogen-activated protein kinase (RAS-MAPK) pathway, including oncogenic However, response to BRAF...
4.
Aziz D, Portman N, Fernandez K, Lee C, Alexandrou S, Llop-Guevara A, et al.
NPJ Breast Cancer
. 2021 Sep;
7(1):111.
PMID: 34465787
Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin...
5.
Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, et al.
J Pathol
. 2020 Sep;
253(1):41-54.
PMID: 32901952
Low-grade serous ovarian carcinoma (LGSOC) is associated with a poor response to existing chemotherapy, highlighting the need to perform comprehensive genomic analysis and identify new therapeutic vulnerabilities. The data presented...
6.
Takenaka M, Kobel M, Garsed D, Fereday S, Pandey A, Etemadmoghadam D, et al.
Clin Cancer Res
. 2019 Apr;
25(13):3962-3973.
PMID: 30967419
Purpose: Although ovarian clear cell carcinomas (OCCC) are commonly resistant to platinum-based chemotherapy, good clinical outcomes are observed in a subset of patients. The explanation for this is unknown but...
7.
McEvoy C, Xu H, Smith K, Etemadmoghadam D, Leong H, Choong D, et al.
J Clin Invest
. 2019 Mar;
129(5):1940-1945.
PMID: 30835257
BRAF and CRAF are critical components of the MAPK signaling pathway which is activated in many cancer types. In approximately 1% of melanomas, BRAF or CRAF are activated through structural...
8.
Aziz D, Etemadmoghadam D, Caldon C, Au-Yeung G, Deng N, Hutchinson R, et al.
Gynecol Oncol
. 2018 Sep;
151(2):327-336.
PMID: 30209015
Objectives: Readily apparent cyclin E1 expression occurs in 50% of HGSOC, but only half are linked to 19q12 locus amplification. The amplified/cyclin E1 subset has intact BRCA1/2, unfavorable outcome, and...
9.
Garsed D, Alsop K, Fereday S, Emmanuel C, Kennedy C, Etemadmoghadam D, et al.
Clin Cancer Res
. 2017 Oct;
24(3):569-580.
PMID: 29061645
Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dramatic and durable response to treatment. We sought to identify clinical, pathological,...
10.
Etemadmoghadam D, Azar W, Lei Y, Moujaber T, Garsed D, Kennedy C, et al.
Cancer Res
. 2017 Jun;
77(16):4268-4278.
PMID: 28646021
Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent...